AbCellera Biologics Investor Relations Material
Latest events
Q2 2025
AbCellera Biologics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from AbCellera Biologics Inc
Access all reports
AbCellera Biologics, Inc. operates as a biotechnology company. The Company offers antibody discovery platform that accelerates the design of therapeutic antibodies and helps researchers discover new treatments for people with cancer or Alzheimer's disease. The company's platform discovers and characterizes fully human antibodies from natural immune responses in order to provide insights into how best to stimulate the human immune system.
Key slides for AbCellera Biologics Inc
Q2 2025
AbCellera Biologics Inc
Q2 2025
AbCellera Biologics Inc
Latest articles
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
Ticker symbol
ABCL
Country
🇺🇸 United States